These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19368530)

  • 1. Shadows across mu-Star? Constitutively active mu-opioid receptors revisited.
    Connor M
    Br J Pharmacol; 2009 Apr; 156(7):1041-3. PubMed ID: 19368530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
    Divin MF; Bradbury FA; Carroll FI; Traynor JR
    Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
    Liu JG; Prather PL
    Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutively active mu-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2,N-MePhe4,Gly-ol5]enkephalin.
    Liu JG; Ruckle MB; Prather PL
    J Biol Chem; 2001 Oct; 276(41):37779-86. PubMed ID: 11500514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
    Liu JG; Prather PL
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment.
    Noble F; Cox BM
    Br J Pharmacol; 1996 Jan; 117(1):161-9. PubMed ID: 8825358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
    Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
    Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
    Wang D; Sun X; Sadee W
    J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma.
    Avidor-Reiss T; Nevo I; Levy R; Pfeuffer T; Vogel Z
    J Biol Chem; 1996 Aug; 271(35):21309-15. PubMed ID: 8702909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of agonist-dependent receptor internalization in the regulation of mu opioid receptors.
    Sternini C; Brecha NC; Minnis J; D'Agostino G; Balestra B; Fiori E; Tonini M
    Neuroscience; 2000; 98(2):233-41. PubMed ID: 10854754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
    Puttfarcken PS; Werling LL; Cox BM
    Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of opioid ligands in cells expressing cloned mu opioid receptors.
    Gharagozlou P; Demirci H; David Clark J; Lameh J
    BMC Pharmacol; 2003 Jan; 3():1. PubMed ID: 12513698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic exposure to morphine and naltrexone induces changes in catecholaminergic neurotransmission in rat brain without altering mu-opioid receptor sensitivity.
    De Vries TJ; Tjon Tien Ril GH; Van der Laan JW; Mulder AH; Schoffelmeer AN
    Life Sci; 1993; 52(21):1685-93. PubMed ID: 8388977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling.
    Yabaluri N; Medzihradsky F
    Mol Pharmacol; 1997 Nov; 52(5):896-902. PubMed ID: 9351981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of adenylyl cyclase activity by mu and delta opioids in rat caudate putamen and nucleus accumbens.
    Izenwasser S; Búzás B; Cox BM
    J Pharmacol Exp Ther; 1993 Oct; 267(1):145-52. PubMed ID: 7901389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways.
    Clark MJ; Harrison C; Zhong H; Neubig RR; Traynor JR
    J Biol Chem; 2003 Mar; 278(11):9418-25. PubMed ID: 12524446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.
    Wang YH; Chai JR; Xu XJ; Ye RF; Zan GY; Liu GY; Long JD; Ma Y; Huang X; Xiao ZC; Dong H; Wang YJ
    Sci Rep; 2018 Sep; 8(1):14087. PubMed ID: 30237513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
    Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
    Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.